Evidence map›Paper›PMID 40063579›Full record

ReviewCurrent opinion in hematology2025

New mechanisms and therapeutic approaches to regulate vascular permeability in systemic inflammation.

Helen H Vu, Samantha A Moellmer, Owen J T McCarty, Cristina Puy

Abstract readReview
In one paragraph

Review in Current opinion in hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. The OCEANIC trial journey: from failure to breakthrough?European heart journal. Cardiovascular pharmacotherapy · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Helen H VuDepartment of Biomedical Engineering.
Samantha A MoellmerDepartment of Biomedical Engineering.
Owen J T McCartyDepartment of Biomedical Engineering.
Cristina PuyDepartment of Biomedical Engineering.

Funding

Characterization of Coagulation Factor-platelet Interactions: Role of FXIR01HL101972 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Owen J McCarty · 2010 to 2026
$8.5M
Contact Pathway Activation on Vascular DevicesR01HL144113 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI HINDS, MONICA T, MCCARTY, OWEN J · 2018 to 2025
$6.0M
Contact Activation and InfectionR01AI157037 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI LUPU, FLOREA, MCCARTY, OWEN J · 2020 to 2024
$3.3M
NHLBI NIH HHS R01 HL101972NHLBI NIH HHS R01 HL144113NIAID NIH HHS R01 AI157037
6 · The paper itself

Abstract

purpose of reviewThis review summarizes mechanisms that regulate endothelial vascular permeability in health and disease. In systemic inflammation, the endothelial barrier integrity is disrupted, which exacerbates vascular permeability, leading to organ failure and death. Herein we provide an overview of emerging therapeutic targets to reverse barrier dysfunction and preserve vascular permeability in inflammatory diseases like sepsis. RECENT

findingsEndothelial barrier function is regulated in part by the endothelial cell-specific protein, Roundabout 4 (ROBO4), and vascular endothelial (VE)-cadherin, a critical adherens junction protein, which act in concert to suppresses vascular permeability by stabilizing endothelial cell-cell interactions. We recently discovered a pathway by which activation of coagulation factor XI (FXI) enhances the cleavage of VE-cadherin by the metalloproteinase ADAM10, contributing to sepsis-related endothelial damage and loss of barrier function. Targeting FXI improved survival and reduced sVE-cadherin levels in a baboon model of sepsis while enhancing Robo4 expression decreased mortality in LPS-treated mice. SUMMARY: Endothelial cell barrier dysfunction is a hallmark of excessive immune responses characteristic of systemic inflammatory diseases such as sepsis. Advances in understanding the molecular mechanisms regulating vascular permeability, for instance the newly discovered roles of FXI or ROBO4, may help identify novel therapeutic targets for mitigating vascular hyperpermeability in septic patients.

Indexed as

Capillary PermeabilityInflammationSepsisAnimalsAntigens, CDCadherin 5CadherinsEndothelial CellsEndothelium, VascularHumansReceptors, Cell SurfaceAntigens, CDCadherin 5CadherinsReceptors, Cell Surface

Identifiers

PMID40063579
PMCPMC11949701

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.